does blue cross cover glp 1 drugs Blue Shield to stop covering popular weight-loss blue cross blue shield fep

To assess heterogeneity, Chi-square and I 2 statistics were utilized, with significant heterogeneity defined as a p -value below 0.1 and an I 2 exceeding 50%

I.BellastellaG.et al (2021b)

Competitive Landscape GLP-1 Weight Loss Drug Market Competitive Landscape: Novo Nordisk and Eli Lilly Duopoly, Oral GLP-1 Challengers, and Telehealth Platforms Reshape the Obesity Drug Market Through 2035 The GLP-1 Weight Loss Drug Market competitive landscape is defined by exceptional concentration at the approved drug tier where Novo Nordisk and Eli Lilly collectively control approximately 87% of global prescription obesity drug revenue combined with intense clinical development competition among more than 40 active GLP-1 pipeline programs

and C.C

Long term outcomes of metabolic/bariatric surgery in adults

Participants in the oral semaglutide arm underwent a dose-escalation schedule (3 mg daily for 4 weeks, followed by 7 mg daily for 4 weeks, then 14 mg daily for the remainder of the trial) to minimize gastrointestinal side effects